Rainmed Medical Limited (HKG:2297)
Hong Kong
· Delayed Price · Currency is HKD 0.1640
0.00 (0.00%)
May 19, 2025, 3:27 PM HKT
Rainmed Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 39.82 | 73.22 | 83.6 | 81.2 |
| Revenue Growth (YoY) | -45.61% | -12.42% | 2.96% | - |
| Cost of Revenue | 15.96 | 24.67 | 13.78 | 12.17 |
| Gross Profit | 23.87 | 48.55 | 69.82 | 69.03 |
| Selling, General & Admin | 97.84 | 145.57 | 176.07 | 185.33 |
| Research & Development | 35.44 | 41.33 | 44.17 | 26.97 |
| Other Operating Expenses | -9.29 | -6.69 | -5.23 | -0.43 |
| Operating Expenses | 124 | 180.21 | 215.01 | 211.87 |
| Operating Income | -100.13 | -131.66 | -145.19 | -142.84 |
| Interest Expense | -0.94 | -1.31 | -0.76 | -3.86 |
| Interest & Investment Income | 3.93 | 12.41 | 3.5 | 1.81 |
| Currency Exchange Gain (Loss) | -0.66 | 1.08 | 2.02 | 0.07 |
| Other Non Operating Income (Expenses) | - | - | -1,211 | -493.87 |
| EBT Excluding Unusual Items | -97.79 | -119.48 | -1,351 | -638.68 |
| Impairment of Goodwill | -5.78 | - | - | - |
| Gain (Loss) on Sale of Investments | 1.25 | 2.4 | 0 | 0.04 |
| Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -0.02 | -0.04 |
| Asset Writedown | -12.98 | - | - | - |
| Pretax Income | -115.3 | -117.09 | -1,351 | -638.69 |
| Income Tax Expense | 0.24 | -0.02 | -5.45 | -5.04 |
| Earnings From Continuing Operations | -115.54 | -117.07 | -1,346 | -633.65 |
| Minority Interest in Earnings | 2.05 | 1.24 | - | 0 |
| Net Income | -113.5 | -115.83 | -1,346 | -633.65 |
| Net Income to Common | -113.5 | -115.83 | -1,346 | -633.65 |
| Shares Outstanding (Basic) | 1,168 | 1,168 | 898 | 643 |
| Shares Outstanding (Diluted) | 1,168 | 1,168 | 898 | 643 |
| Shares Change (YoY) | - | 30.01% | 39.63% | - |
| EPS (Basic) | -0.10 | -0.10 | -1.50 | -0.99 |
| EPS (Diluted) | -0.10 | -0.10 | -1.50 | -0.99 |
| Free Cash Flow | -128.5 | -208.97 | -128.33 | -103.67 |
| Free Cash Flow Per Share | -0.11 | -0.18 | -0.14 | -0.16 |
| Gross Margin | 59.93% | 66.31% | 83.52% | 85.02% |
| Operating Margin | -251.43% | -179.81% | -173.66% | -175.91% |
| Profit Margin | -284.99% | -158.20% | -1609.93% | -780.36% |
| Free Cash Flow Margin | -322.68% | -285.40% | -153.50% | -127.67% |
| EBITDA | -82.02 | -115.1 | -134.39 | -136.74 |
| EBITDA Margin | -205.94% | -157.20% | -160.74% | -168.40% |
| D&A For EBITDA | 18.11 | 16.56 | 10.8 | 6.1 |
| EBIT | -100.13 | -131.66 | -145.19 | -142.84 |
| EBIT Margin | -251.43% | -179.81% | -173.66% | -175.91% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.